Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* Subjects who have received dTpa vaccine or Td and pa vaccines in study 263855/002 .~* A male or female subject, recruited 10 years (+/- 9 months) after booster vaccination in study 263855/002.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* If the subject is female, she must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of booster vaccination.~* Written informed consent obtained from the subject.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.~* Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination, or planned administration during the active study period~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product~* Previous booster vaccination against diphtheria, tetanus or pertussis since the last dose received in study 263855/002~* History of diphtheria, tetanus, or pertussis diseases.~* Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.~* Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.~* Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :- hypersensitivity reaction to any component of the vaccine; - encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine; - fever ≥ 40 °C (axillary temperature) within 48 hours of vaccination not due to another identifiable cause; - collapse or shock-like state within 48 hours of vaccination; - convulsions with or without fever, occurring within 3 days of vaccination.~* Acute disease at the time of enrolment.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 28 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Boostrix I Group (Type: EXPERIMENTAL): Subjects who had received the Boostrix™ vaccine in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the same vaccine, intramuscularly in the deltoid region of the non-dominant arm.
- Boostrix II Group (Type: ACTIVE_COMPARATOR): Subjects who had received the Td vaccines in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the Boostrix™ vaccine intramuscularly in the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).